Patent · US Active

Crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]THIO]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide

US8748603B2 · kind B2 · utility

1Cited by

0References

7Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Britt Anne Ingela Gullberg · Lund, SE
Thomas Larsson · Luleå, SE
Jeffrey Paul Stonehouse · Coalville, GB

Key dates

Filing date	Jul 12, 2011
Grant date	Jun 10, 2014
Priority date	—
Expiry date	Apr 7, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]thio]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]1-azetidinesulfon-amide anhydrate. Such compounds/forms may be useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.